Sunday, February 1, 2015

Vital Therapies Phase 3 trial hits enrolment target

Vital Therapies Phase 3 trial hits enrolment target

January 30, 2015 by · Leave a Comment 

Tweet Vital Therapies (NASDAQ:VTL) has reached the 200 subject enrollment target in VTI-208, its randomized, open-label Phase 3 clinical trial in alcohol induced liver decompensation. “Executing on VTI-208 has been our primary focus over the last two years at about 50 leading hospitals in the U.S., Europe and Australia,” Terry Winters, CEO and co-chairman, said […]

Roth resumes coverage of Neptune at buy

Roth resumes coverage of Neptune at buy

January 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX:NTB) with a “buy” rating and $5 price target. The stock closed at $1.83 on Thursday. Neptune is a leading provider of krill oil (omega-3 supplements) with its premium product, Neptune Krill Oil (NKO). “With a new state-of-the-art manufacturing plant, and a […]

Nuvo cites placebo effect in WF10 trial

Nuvo cites placebo effect in WF10 trial

January 30, 2015 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) cited a placebo effect for its WF10 failing to achieve statistical significance in a Phase 2 trial in Germany for the treatment of refractory allergic rhinitis. Each of the active arms in the study demonstrated a greater reduction in total nasal symptom score (TNSS) than placebo. However, the difference between the […]

Neovasc upsizes offering due to market interest

Neovasc upsizes offering due to market interest

January 29, 2015 by · Leave a Comment 

Tweet Due to market interest, Neovasc (NASDAQ:NVCN; TSX:NVC) has increased the size of its previously announced public offering to 10.5 million common shares from eight million shares at a price of $7.19 each for gross proceeds of $63.6-million for the company and $11.9-million for certain directors, officers and employees. The company is selling 8,840,000 of […]

Enlivex gets EMA orphan drug status for ApoCell

Enlivex gets EMA orphan drug status for ApoCell

January 28, 2015 by · Leave a Comment 

Tweet Enlivex Therapeutics, a member of the Hadasit Bio-Holdings group (TASE:HDST; OTCQB:HDASY), has received orphan drug status from the European Medicines Agency (EMA) for its lead product candidate, ApoCell, for the prevention of Graft-versus-host Disease (GvHD). ApoCell already has orphan drug designation from the FDA. The company plans to initiate a Phase 2b/3 trial of […]

TearLab names Raymond Kong as VP sales

TearLab names Raymond Kong as VP sales

January 28, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Raymond Kong to its senior management team as VP of Sales. He succeeds Duane Morrison, who will shift his focus to major accounts and doctor networks in the newly created position of VP of business development. Most recently, Mr. Kong served as general manager for Alcon Laboratories’ Indonesia business, […]

Provectus gets Chinese process patent allowance

Provectus gets Chinese process patent allowance

January 26, 2015 by · Leave a Comment 

Tweet Provectus Biopharmaceuticals (NYSE MKT:PVCT) has received notification of allowance from the Chinese Patent Office for its application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the company’s lead oncology drug candidate. The pending Chinese patent covers the same process as the one granted […]

Actinium submits pre-IND meeting request to FDA

Actinium submits pre-IND meeting request to FDA

January 26, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) has submitted a request for a pre-IND meeting to the FDA for the company’s Iomab-B drug candidate currently undergoing final preparations to start a pivotal Phase 3 trial in mid-2015. The initial indication for Iomab-B is conditioning for bone marrow transplant in older relapsed and refractory acute myeloid leukemia patients, […]

Knight in financing pact with Synergy Strips

Knight in financing pact with Synergy Strips

January 23, 2015 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has entered into a $6-million senior secured debt financing agreement with Synergy Strips, a U.S. company focused on the health and wellness sector. The secured loan will finance Synergy’s acquisition of the FOCUSfactor brand, the No. 1 brain health supplement in the U.S. The loan will bear interest at 15% a […]

Cellectar fluorescence agents in peer-reviewed journal

Cellectar fluorescence agents in peer-reviewed journal

January 22, 2015 by · Leave a Comment 

Tweet Cellectar Biosciences (NASDAQ:CLRB) has announced publication of the first peer-reviewed proof-of-principle study of a new class of fluorescent alkylphosphocholine analogs for fluorescence guided glioma surgery in Neurosurgery, official journal of the Congress of Neurological Surgeons. The study is featured on the cover of the February 2015 issue, and demonstrates that the fluorescent cancer-selective CLR1501 and […]

Next Page »

Email Newsletters with Constant Contact
Google+